Table 1.

Baseline characteristics of a cohort of new users of H2 blockers, and new users of PPI

Baseline CharacteristicsH2 Blockers (n=20,270)PPI (n=173,321)P Value
Age (SD)55.40 (12.81)56.85 (11.85)P<0.001
Baseline eGFR in ml/min per 1.73 m2 (SD)86.98 (15.88)86.56 (15.67)P<0.001
RaceWhite (%)15,937 (78.62)137,174 (79.14)P=0.01
Black (%)3,784 (18.67)32,018 (18.47)
Other (%)549 (2.71)4,129 (2.38)
SexMale (%)18,929 (93.38)161,259 (93.04)P=0.07
Female (%)1,341 (6.62)12,062 (6.96)
Diabetes mellitus (%)8,923 (44.02)72,309 (41.72)P<0.001
Hypertension (%)15,814 (78.02)136,782 (78.92)P<0.01
Chronic lung disease (%)7,951 (39.23)66,955 (38.63)P=0.10
Peripheral artery disease (%)5,009 (24.71)31,311 (18.07)P<0.001
Cardiovascular disease (%)8,459 (41.73)71,807 (41.43)P=0.41
Cerebrovascular disease (%)4,596 (22.67)26,457 (15.26)P<0.001
Dementia (%)5,058 (24.95)32,380 (18.68)P<0.001
Hyperlipidemia (%)14,785 (72.94)127,463 (73.54)P=0.07
Hepatitis C (%)1,198 (5.91)14,892 (8.59)P<0.001
HIV (%)55 (0.27)678 (0.39)P<0.01
Gastroesophageal reflux disease (%)3,767 (18.58)86,804 (50.08)P<0.001
Upper gastrointestinal tract bleeding (%)246 (1.21)7,898 (4.56)P<0.001
Ulcer disease (%)666 (3.29)26,228 (15.13)P<0.001
H. pylori infection (%)22 (0.11)4,052 (2.34)P<0.001
Barrett esophagus (%)15 (0.07)3,207 (1.85)P<0.001
Achalasia (%)1 (0.00)214 (0.12)P<0.001
Stricture (%)33 (0.16)2,299 (1.33)P<0.001
Esophageal adenocarcinoma (%)3 (0.01)291 (0.17)P<0.001
Years of follow-up (IQR)5.00 (5.00, 5.00)5.00 (5.00, 5.00)P<0.001
Days of having related prescription during follow-up (IQR)90 (30, 270)450 (90, 1260)P<0.001
  • IQR, interquartile range.